# TYRA — Tyra Biosciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** TYRA  
**Sources:** 18  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-tyra-tyra-biosciences-inc-catalysts-narrative-risks-10378

---

## Overview (as of the reference date, 2026-10-31)

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company headquartered in Carlsbad, California, focused on Fibroblast Growth Factor Receptor (FGFR) biology [[1]](https://finance.yahoo.com/healthcare/articles/tyra-biosciences-host-conference-call-120000401.html)[[4]](https://www.morningstar.com/news/pr-newswire/20260804la18882/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights). It trades on the Nasdaq, carries a market capitalization of roughly $1.48B, and its shares were quoted around $21.07 (having fallen from a 52-week high of ~$40.65) [[15]](https://askthedate.com/America/New_York/en/earnings-calendar/2026-11-11/TYRA/). The company's lead candidate is oral dabogratinib, described as a potential first-in-class selective FGFR3 inhibitor, developed through its proprietary SNÅP precision-medicine platform [[1]](https://finance.yahoo.com/healthcare/articles/tyra-biosciences-host-conference-call-120000401.html)[[16]](https://www.marketbeat.com/earnings/reports/2026-8-13-tyra-biosciences-inc-stock/).

## Key recent catalysts (approximately August–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-tyra-tyra-biosciences-inc-catalysts-narrative-risks-10378 (free to sign up)._